JP2019534858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534858A5 JP2019534858A5 JP2019513444A JP2019513444A JP2019534858A5 JP 2019534858 A5 JP2019534858 A5 JP 2019534858A5 JP 2019513444 A JP2019513444 A JP 2019513444A JP 2019513444 A JP2019513444 A JP 2019513444A JP 2019534858 A5 JP2019534858 A5 JP 2019534858A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ligand according
- peptide
- ligand
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 claims description 88
- 206010028980 Neoplasm Diseases 0.000 claims description 62
- 201000011510 cancer Diseases 0.000 claims description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
- 150000001413 amino acids Chemical class 0.000 claims description 44
- 235000001014 amino acid Nutrition 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 22
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 20
- 210000000130 stem cell Anatomy 0.000 claims description 20
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims description 12
- 102100039676 Frizzled-7 Human genes 0.000 claims description 12
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims description 12
- 101000643895 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 6 Proteins 0.000 claims description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 12
- 102100021015 Ubiquitin carboxyl-terminal hydrolase 6 Human genes 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 230000004927 fusion Effects 0.000 claims description 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 230000002018 overexpression Effects 0.000 claims description 12
- 201000002528 pancreatic cancer Diseases 0.000 claims description 12
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 108050007985 Frizzled-7 Proteins 0.000 claims description 8
- 102100028461 Frizzled-9 Human genes 0.000 claims description 8
- 101001061405 Homo sapiens Frizzled-9 Proteins 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 102100021259 Frizzled-1 Human genes 0.000 claims description 4
- 102100021261 Frizzled-10 Human genes 0.000 claims description 4
- 102100021265 Frizzled-2 Human genes 0.000 claims description 4
- 102100039820 Frizzled-4 Human genes 0.000 claims description 4
- 102100039818 Frizzled-5 Human genes 0.000 claims description 4
- 102100039799 Frizzled-6 Human genes 0.000 claims description 4
- 102100028466 Frizzled-8 Human genes 0.000 claims description 4
- 101000819438 Homo sapiens Frizzled-1 Proteins 0.000 claims description 4
- 101000819451 Homo sapiens Frizzled-10 Proteins 0.000 claims description 4
- 101000819477 Homo sapiens Frizzled-2 Proteins 0.000 claims description 4
- 101000819458 Homo sapiens Frizzled-3 Proteins 0.000 claims description 4
- 101000885581 Homo sapiens Frizzled-4 Proteins 0.000 claims description 4
- 101000885585 Homo sapiens Frizzled-5 Proteins 0.000 claims description 4
- 101000885673 Homo sapiens Frizzled-6 Proteins 0.000 claims description 4
- 101001061408 Homo sapiens Frizzled-8 Proteins 0.000 claims description 4
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical group 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 4
- 125000005473 octanoic acid group Chemical group 0.000 claims description 4
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- FMUMEWVNYMUECA-LURJTMIESA-N (2s)-2-azaniumyl-5-methylhexanoate Chemical group CC(C)CC[C@H](N)C(O)=O FMUMEWVNYMUECA-LURJTMIESA-N 0.000 claims description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical group C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims description 2
- SLVKVPLSFLVIOD-UHFFFAOYSA-N 2-amino-3-decoxypropanoic acid Chemical compound NC(C(=O)O)COCCCCCCCCCC SLVKVPLSFLVIOD-UHFFFAOYSA-N 0.000 claims description 2
- JINGUCXQUOKWKH-UHFFFAOYSA-N 2-aminodecanoic acid Chemical compound CCCCCCCCC(N)C(O)=O JINGUCXQUOKWKH-UHFFFAOYSA-N 0.000 claims description 2
- OLUWXTFAPJJWPL-YFKPBYRVSA-N 6-hydroxy-l-norleucine Chemical compound OC(=O)[C@@H](N)CCCCO OLUWXTFAPJJWPL-YFKPBYRVSA-N 0.000 claims description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 2
- FMUMEWVNYMUECA-UHFFFAOYSA-N L-homoleucine Natural products CC(C)CCC(N)C(O)=O FMUMEWVNYMUECA-UHFFFAOYSA-N 0.000 claims description 2
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical group OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 210000004966 intestinal stem cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000000441 neoplastic stem cell Anatomy 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385848P | 2016-09-09 | 2016-09-09 | |
| US62/385,848 | 2016-09-09 | ||
| US201662419331P | 2016-11-08 | 2016-11-08 | |
| US62/419,331 | 2016-11-08 | ||
| PCT/US2017/050841 WO2018049275A1 (en) | 2016-09-09 | 2017-09-08 | Selective peptide inhibitors of frizzled |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534858A JP2019534858A (ja) | 2019-12-05 |
| JP2019534858A5 true JP2019534858A5 (enExample) | 2020-10-22 |
Family
ID=60022161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513444A Pending JP2019534858A (ja) | 2016-09-09 | 2017-09-08 | Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190359653A1 (enExample) |
| EP (1) | EP3509616A1 (enExample) |
| JP (1) | JP2019534858A (enExample) |
| CN (1) | CN110198729A (enExample) |
| WO (1) | WO2018049275A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020102664A1 (en) * | 2018-11-16 | 2020-05-22 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Biomarkers and treatment of neuronal injury and neurodegeneration |
| CN112159474B (zh) * | 2019-11-06 | 2021-11-19 | 上海健康医学院 | 一种靶向Frizzled7人源化抗体及其制备方法与应用 |
| WO2025100520A1 (ja) * | 2023-11-10 | 2025-05-15 | ペプチドリーム株式会社 | ペプチド、ペプチド複合体、医薬組成物、細胞培養用組成物、及び医療用、診断用又は研究用に用いられる組成物 |
| CN121800875A (zh) * | 2025-11-24 | 2026-04-07 | 南方科技大学 | 一种双重抑制肿瘤Wnt信号通路的纳米多肽材料及其制备方法与应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| DE3587814T2 (de) | 1985-03-30 | 1994-11-10 | Marc Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5498538A (en) | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| AU7104294A (en) | 1994-06-10 | 1996-01-05 | Symbiotech, Inc. | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage |
| US5627024A (en) | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| IL126045A0 (en) | 1996-03-20 | 1999-05-09 | Dyax Corp | Purification of tissue plasminogen activator (tpa) |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| EP0954531A1 (en) | 1996-06-06 | 1999-11-10 | Lajolla Pharmaceutical Company | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES |
| AU735015B2 (en) | 1996-06-10 | 2001-06-28 | Scripps Research Institute, The | Use of substrate subtraction libraries to distinguish enzyme specificities |
| US5766905A (en) | 1996-06-14 | 1998-06-16 | Associated Universities Inc. | Cytoplasmic bacteriophage display system |
| WO1998014277A1 (en) | 1996-10-04 | 1998-04-09 | Whatman, Inc. | Device and method for simultaneous multiple chemical syntheses |
| EP0934526B1 (en) | 1996-10-08 | 2003-01-08 | U-BISys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
| CA2270869A1 (en) | 1996-11-06 | 1998-05-14 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| IL119586A (en) | 1996-11-07 | 2001-09-13 | Univ Ramot | Discontinuous library of a single biological unit and a method for its preparation |
| IL119587A (en) | 1996-11-07 | 2000-12-06 | Univ Ramot | Method of preparing and for obtaining bimolecular interactions |
| ATE230277T1 (de) | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
| BR9908226A (pt) | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| WO2006036175A2 (en) * | 2004-09-21 | 2006-04-06 | Rhode Island Hospital, A Lifespan-Partner | Wnt proteins and detection and treatment of cancer |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| EP2331136B1 (en) * | 2008-09-26 | 2018-01-10 | OncoMed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| CN102971337B (zh) * | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| AU2014306564B2 (en) * | 2013-08-14 | 2019-10-17 | Antlera Therapeutics Inc. | Antibodies against frizzled proteins and methods of use thereof |
| EP2975047A1 (en) * | 2014-07-18 | 2016-01-20 | Université de Lausanne | Wnt7a polypeptides and their use |
-
2017
- 2017-09-08 JP JP2019513444A patent/JP2019534858A/ja active Pending
- 2017-09-08 WO PCT/US2017/050841 patent/WO2018049275A1/en not_active Ceased
- 2017-09-08 EP EP17780550.4A patent/EP3509616A1/en not_active Withdrawn
- 2017-09-08 CN CN201780065292.9A patent/CN110198729A/zh active Pending
-
2019
- 2019-03-04 US US16/292,099 patent/US20190359653A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019196365A5 (enExample) | ||
| ES2383824T3 (es) | Inhibidores peptídicos con permeabilidad celular de la ruta de transducción de la señal JNK | |
| AU2019253863A1 (en) | Cysteine engineered fibronectin type III domain binding molecules | |
| EP1911458B9 (en) | Cell-permeable peptide inhibitors of the JNK signal transduction pathway | |
| JP2016052315A5 (enExample) | ||
| JP2012509659A5 (enExample) | ||
| JP2016187356A5 (enExample) | ||
| US20240294590A1 (en) | Nucleic acid encoding genetically engineered growth factor variants | |
| JP2022514687A5 (enExample) | ||
| JP2019535763A5 (enExample) | ||
| JP2010053136A5 (enExample) | ||
| JP2010519176A5 (enExample) | ||
| JP2017514812A5 (enExample) | ||
| JP2017501130A5 (enExample) | ||
| RU2011110405A (ru) | Агенты, связывающие рецептор frizzled и их применение | |
| JP2017529097A5 (enExample) | ||
| JP2016506911A (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| BR112019021056B1 (pt) | Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular | |
| JP2010536714A5 (enExample) | ||
| JP2022502347A (ja) | 細胞透過性ペプチド | |
| CN108699110A (zh) | 整合素结合肽及其用途 | |
| CN116134138B (zh) | 靶向细胞内诱瘤蛋白的抗体、或其单链可变片段与癌细胞穿透肽的融合蛋白、及其用途 | |
| JP2018537117A5 (enExample) | ||
| JP2011523405A5 (enExample) | ||
| JP2010537623A5 (enExample) |